Taking either one of the antihypertensive medications lisinopril or carvedilol when initiating treatment with trastuzumab did not appear to prevent heart function decline in patients with breast cancer, but a subgroup of patients who were also receiving anthracycline-based chemotherapy in addition to trastuzumab benefitted with a significantly reduced risk of heart damage, according to a study.
The latest-generation left ventricular assist device (LVAD) HeartMate 3 is clinically superior to its predecessor HeartMate II in improving survival at 2 years free of disabling stroke or reoperation due to device malfunction in patients with advanced heart failure (HF), the MOMENTUM* 3 trial has shown.
The interleukin-1 beta (IL-1β) inhibitor canakinumab did not prevent the progression from pre-diabetes to diabetes in patients with prior myocardial infarction (MI), according to results of the CANTOS* trial.
The use of aspirin in older patients with type 2 diabetes (T2D) and heart failure appears to reduce mortality risk but paradoxically increases the rates of nonfatal myocardial infarction (MI) and stroke, according to a retrospective analysis of health records presented at ACC.18.
Delayed administration of ticagrelor after fibrinolysis appears to be as safe as clopidogrel with regards to TIMI* major bleeding risk at 30 days in patients younger than 75 years with ST-segment elevation myocardial infarction (STEMI), according to the TREAT** trial. However, there were more minor and minimal bleeding events with ticagrelor than with clopidogrel.
Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.
Not only does treatment with the PCSK9* inhibitor alirocumab reduces cardiovascular (CV) events along with plunges in LDL-C levels, it was also associated with a reduced risk of all-cause mortality compared with placebo in patient with a recent acute coronary syndrome (ACS) and persistently high cholesterol despite maximal statin therapy, according to top-line results from the ODYSSEY** Outcomes trial.
The experimental reversal agent andexanet alfa effectively reversed the anticoagulant effect of factor Xa (fXa) inhibitors by controlling serious bleeding events, according to interim results of the ANNEXA-4* trial presented at the American College of Cardiology Annual Scientific Session & Expo (ACC.18) in Orlando, Florida, US.
Patients with acute coronary syndrome (ACS) who received a 6-month course of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) fared similarly to those who received the standard ≥12-month DAPT course with regards to incidence of major adverse cardiovascular and cerebrovascular events 18 months post-procedure, according to results from the SMART-DATE* trial. However, a higher incidence of myocardial infarction (MI) with 6-month DAPT precludes it from replacing the standard course.